Did you know?

Wegovy is the new Rybelsus and is available now. Get started below.
Start free assessment
Wegovy now in stock
Trusted NHS provider
Dedicated support team
24h-tracked & delivery
Trusted NHS provider
Dedicated support team
Start free assessment

Can you buy Rybelsus tablets 
for weight loss?

Everything you need to know
about Rybelsus, weight loss, 
and type 2 diabetes
Did you know? Wegovy is the new Rybelsus and is available now. Get started below.

Rybelsus tablets are not available for weight loss treatment in the UK

About Rybelsus tablets

Prescription Rybelsus (semaglutide) 
in the UK
Rybelsus is the brand name for oral semaglutide, which comes in tablet form. This medication is licensed for the treatment of type 2 diabetes, and has been shown to help patients control blood sugar and achieve weight loss (1). You can buy Rybelsus for the treatment of type 2 diabetes in the UK if you have a prescription, or get it via the NHS if you’re eligible.

Rybelsus is not currently licensed for weight loss in the UK.

Who is Habitual?

Habitual provides two types of programmes:
  • Medication-based weight loss programmes which include a prescription, medication, and access to our behavioural resources including a mobile app and community support.
  • Type 2 diabetes remission programmes which combine total diet replacement with the same digital services included in medication plans.
Habitual does not prescribe Rybelsus for weight loss, as it is only licensed for type 2 diabetes. Wegovy contains the same compound (semaglutide) and is available as an injection.
Explore our Wegovy plan

The Habitual app

Expert-written content
Access science-backed behavioural lessons to make lasting changes to your nutrition, exercise routine, sleep, and psychology.

The Habitual app

Progress dashboard
Celebrate your wins daily, no matter how small. See your weight drop and your habits improve over time.

The Habitual app

Daily tracking
Weight is only one aspect of health. Achieve lasting change by tracking your habits daily.

The Habitual app

Earn points and build a streak when you take actions in the app... then redeem them for real-life rewards!

The Habitual app

Browse simple, low-calorie recipes and create your meal plan with a few taps to auto-generate your shopping list.


More information about Rybelsus (semaglutide)


[1] Vanita R. Aroda, Julio Rosenstock, Yasuo Terauchi, Yuksel Altuntas, Nebojsa M. Lalic, Enrique C. Morales Villegas, Ole K. Jeppesen, Erik Christiansen, Christin L. Hertz, Martin Haluzík, PIONEER 1 Investigators; PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care 1 September 2019; 42 (9): 1724–1732. (Reference)

[2] Helena W. Rodbard, Julio Rosenstock, Luis H. Canani, Chaicharn Deerochanawong, Janusz Gumprecht, Søren Østergaard Lindberg, Ildiko Lingvay, Anette Luther Søndergaard, Marianne Bach Treppendahl, Eduard Montanya, PIONEER 2 Investigators; Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Diabetes Care 1 December 2019; 42 (12): 2272–2281.(Reference)

[3] Filip K Knop, Vanita R Aroda, Ruben D do Vale, Thomas Holst-Hansen, Peter N Laursen, Julio Rosenstock, Domenica M Rubino, W Timothy Garvey; Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 2023. ISSN 0140-6736 (Reference)

[4] Pratley R, Amod A, Hoff ST, Kadowaki T, Lingvay I, Nauck M, Pedersen KB, Saugstrup T, Meier JJ; PIONEER 4 investigators. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019 Jul 6;394(10192):39-50. doi: 10.1016/S0140-6736(19)31271-1. Epub 2019 Jun 8. Erratum in: Lancet. 2019 Jul 6;394(10192):e1. PMID: 31186120.

[5] Leslie, W.S., Ford, I., Sattar, N. et al. The Diabetes Remission Clinical Trial (DiRECT): protocol for a cluster randomised trial. BMC Fam Pract 17, 20 (2016). (Reference)